ImmunoPrecise Antibodies (NASDAQ:IPA) Shares Down 1%

Shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) traded down 1% during trading on Tuesday . The company traded as low as $0.98 and last traded at $0.99. 43,161 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 327,960 shares. The stock had previously closed at $1.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Benchmark reissued a “speculative buy” rating and issued a $5.00 price target on shares of ImmunoPrecise Antibodies in a research note on Friday, March 15th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of ImmunoPrecise Antibodies in a research note on Friday, March 15th.

ImmunoPrecise Antibodies Trading Down 2.2 %

The stock has a market capitalization of $25.22 million, a P/E ratio of -2.34 and a beta of 0.10. The company has a current ratio of 1.66, a quick ratio of 1.38 and a debt-to-equity ratio of 0.25. The stock’s fifty day moving average price is $1.08 and its two-hundred day moving average price is $1.42.

Institutional Investors Weigh In On ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC boosted its position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 24.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,281,305 shares of the company’s stock after buying an additional 253,052 shares during the quarter. Ingalls & Snyder LLC owned approximately 4.87% of ImmunoPrecise Antibodies worth $2,191,000 as of its most recent filing with the Securities & Exchange Commission. 6.70% of the stock is currently owned by institutional investors and hedge funds.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.